Vijayan Veena, M Unagolla Janitha, Panchal Dhruvisha, John Judith Eloyi, Menon Siddharth S, Menon Jyothi U
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island Kingston RI 02881 USA
International Academy East Troy MI 48083 USA.
RSC Pharm. 2025 Apr 28. doi: 10.1039/d5pm00044k.
Liver fibrosis is a progressive and fatal condition characterized by stiffness and scarring of the liver due to excessive buildup of extracellular matrix (ECM) proteins. If left untreated, it can progress to liver cirrhosis and hepatocellular carcinoma (HCC)-one of the fastest-rising causes of cancer mortality in the United States. Despite the increased prevalence of liver fibrosis due to infections, exposure to toxins, and unhealthy lifestyles, there are no effective treatments available. Recent advances in nanomedicine can lead to more targeted and effective strategies for treating liver diseases than existing treatments. In particular, the use of biomimetic nanoparticles (NPs) such as liposomes and cell-membrane-coated NPs is of interest. NPs functionalized with cell membranes mimic the properties of the source cell used and provide inherent immune evasion ability, homologous adhesion, and prolonged circulation. This review explores the types of biomimetic coatings, different cargoes delivered through biomimetic NPs for various treatment modalities, and the type of core NPs used for targeting liver fibrosis and HCC.
肝纤维化是一种渐进性致命疾病,其特征是由于细胞外基质(ECM)蛋白过度积累导致肝脏变硬和形成瘢痕。如果不进行治疗,它会发展为肝硬化和肝细胞癌(HCC),而HCC是美国癌症死亡率上升最快的原因之一。尽管由于感染、接触毒素和不健康的生活方式导致肝纤维化的患病率有所增加,但目前尚无有效的治疗方法。与现有治疗方法相比,纳米医学的最新进展可以带来更具针对性和有效性的肝病治疗策略。特别是,使用仿生纳米颗粒(NPs),如脂质体和细胞膜包被的NPs,备受关注。用细胞膜功能化的NPs模仿所用源细胞的特性,并提供固有的免疫逃逸能力、同源粘附和延长循环时间。本文综述探讨了仿生涂层的类型、通过仿生NPs用于各种治疗方式的不同载药、以及用于靶向肝纤维化和HCC的核心NPs类型。